Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) has been granted Priority Review by China's National Medical…





